arrow
И

И. А. Покатаев

moscow city hospital
H指数:9
被引数:430

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicenter Prospective Phase II Study of Induction Therapy With Pembrolizumab, Cisplatin, and Fluorouracil in Patients With Locally Advanced Head and Neck Cancer

多中心前瞻性II期研究:采用帕博利珠单抗、顺铂和氟尿嘧啶对局部晚期头颈癌患者进行诱导治疗

2026-05-010
PRE
Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

avelumab维持治疗转移性尿路上皮癌:肿瘤部位和既往手术是否重要?

2025-08-280
PRE
Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study

avelumab维持治疗用于转移性尿路上皮癌患者的疗效:一项真实世界、前瞻性回顾性混合设计的RAVE-Bladder研究

2025-02-140
OAAI
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma

Belztifan在晚期透明细胞肾细胞癌患者中的随机II期剂量比较LITESPARK-013研究

2024-12-010
PRE
Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease

仑伐替尼和帕博利珠单抗在治疗高肿瘤负荷的转移性肾细胞癌患者中的一线治疗真实世界疗效

2024-12-010
PRE
Real-world efficacy of induction chemotherapy followed by chemoradiotherapy compared to concurrent chemoradiation therapy in patients with very advanced head and neck squamous cell cancer

真实世界中,诱导化疗后序贯化疗放疗与同步放化疗在极晚期头颈鳞状细胞癌患者中的疗效比较

2024-12-010
PRE
A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy

一项多中心随机临床试验,评估接受抗-EGFR治疗的RAS/BRAF野生型转移性结直肠癌患者的阴性超选择。

2024-09-010
PRE
Propensity-score matching analysis for efficacy of platinum-based versus non-platinum chemotherapy in patients with platinum-resistant ovarian cancer (PROC): Real-world recent cohort study

倾向性评分匹配分析铂类为基础与非铂类化疗在铂耐药性卵巢癌患者中的疗效(PROC):真实世界近期队列研究

2024-09-010
PRE
Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results

公共知识库在综合性肿瘤分子谱分析结果解读中的应用价值

2023-02-080
PRE